Vasculogenic mimicry and aberrant expression of HIF-lα/E-cad are associated with worse prognosis of esophageal squamous cell carcinoma
Vasculogenic mimicry and aberrant expression of HIF-lα/E-cad are associated with worse prognosis of esophageal squamous cell carcinoma
复制标题
DOI：
10.1007/s11596-013-1129-4
复制
发表时间：
2013-06-01
影响因子：
--
通讯作者：
Tao, Yi-sheng
中科院分区：
文献类型：
--
作者：
Chai, Da-min;Bao, Zheng-qi;Tao, Yi-sheng
本研究旨在寻找预测食管鳞癌(ESCC)患者预后的良好指标。免疫组织化学染色观察食管鳞癌血管生成拟态(Vm)和缺氧诱导因子-Lα(HIF-Lα)/E-cad蛋白的表达。分析Vm、低氧诱导因子-Lα/E-cad与食管癌临床病理特征及5年生存率的关系。本研究共收集食管鳞癌组织160例，正常食管壁组织28例作为对照。在160例食管鳞癌标本中，78例(48.75%)检出Vm通道，正常食管壁均未发现Vm。食管鳞癌组织中HIF-Lα和E-cad的高表达率分别为43.75%和38.75%，对照组分别为17.86%和71.43%(P均<0.05)。Vm、HIF-Lα和E-cad的表达水平与鳞癌患者的淋巴结转移、浆膜浸润、PTNM分期和5年生存率显著相关(均P<；0.05)。Vm与缺氧诱导因子-Lα呈正相关，与E-cad呈负相关，与E-cad呈负相关(P<；0.001)。鳞癌患者5年生存率分别为6.41%(5/78)、65%(52/82)、7.14%(5/70)、57.78%(52/90)。E-cad高表达组5年生存率为80.65%(50/62)，低表达组为7.37%(7/98)(P均0.05)。COX多因素回归分析显示，淋巴结转移、PTNM分期、Vm、HIF-Lα和E-cad表达水平是食管癌的独立危险因素(均P<；0.05)。Vm、HIF-Lα和E-cad的联合检测对预测食管癌的侵袭、转移和预后有重要意义。
This study aims to find good markers for predicting the prognosis of patients with esophageal squamous cell carcinoma (ESCC). Vasculogenic mimicry (VM) and the expression of hypoxia inducible factor-l alpha (HIF-l alpha)/E-cad protein in ESCC were investigated by immunostaining. The association between VM, HIF-l alpha/E-cad and clinicopathologic characteristics and 5-year-survival rate of patients with ESCC was analyzed. A total of 160 ESCC specimens were involved in this study and 28 specimens of normal esophageal mucosa served as controls. VM channels were identified in 78 (48.75%) of the 160 ESCC specimens and none of the normal esophageal mucosa was found to have VM. The rates of high-expression of HIF-l alpha and E-cad in ESCC were 43.75% and 38.75%, while the rates in control were 17.86% and 71.43%, respectively (P < 0.05 for all). VM and the expression levels of HIF-l alpha and E-cad were significantly related to lymph node metastasis, serosa infiltration, PTNM staging and 5-year-survival rates of patients with ESCC (P < 0.05 for all). VM was positively correlated with HIF-l alpha but negatively with E-cad, and HIF-l alpha was negatively correlated with E-cad (P < 0.001 for all). The 5-year-survival rate of patients with ESCC was 6.41% (5/78) in VM group and 65% (52/82) in non-VM group, 7.14% (5/70) in high HIF-l alpha expression group and 57.78% (52/90) in low HIF-l alpha expression group. Oppositely, the 5-year-survival rate in high E-cad expression group was 80.65% (50/62) and that in low E-cad expression group was 7.37% (7/98) (P < 0.05 for all). Cox multifactor regression analysis indicated that lymph node metastasis, PTNM stage, VM and expression levels of HIF-l alpha and E-cad were independent risk factors of patients with ESCC (P < 0.05 for all). Combined detection of VM, HIF-l alpha and E-cad plays an important role in predicting the invasion, metastasis and prognosis of patients with ESCC.